Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Early-Stage Breast Carcinoma|HER-2 Positive Breast Cancer
Interventions: DRUG: docetaxel + trastuzumab sc + pertuzumab|DRUG: trastuzumab emtansin
Sponsor: Thomas Hatschek